Chronic Obstructive Pulmonary Disease
Researchers examined real-world characteristics of patients receiving albuterol multidose dry powder inhaler or short-acting β2 agonists with short-acting β2 agonists for asthma and chronic obstructive pulmonary disease.
Use of long-acting bronchodilators is linked to cardiovascular risks in patients with COPD.
A middle-aged patient with morbid obesesity and COPD complains about having shortness of breath at rest and dyspnea on exertion.
Results support the benefits of single-inhaler triple therapy compared with inhaled corticosteroid/long-acting β2-agonist therapy in patients with advanced COPD.
The COPD Foundation has released tips for patients with COPD to avoid pneumonia and exacerbations.
Results show that exposure to pesticides and herbicides is associated with fixed airflow obstruction and chronic bronchitis.
Researchers found that doxycycline plus prednisone did not prolong the time between exacerbations in patients with COPD.
A chest CT can provide additional information on comorbidities, including coronary artery disease and osteoporosis.
Patients are more likely to exercise and participate in pulmonary rehabilitation if they live with others and have a caregiver.
LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid.
Users of opioid-only agents had significantly increased rates of emergency room visits and hospitalizations for ischemic heart disease and IHD-related mortality.
Cardiac geometry demonstrated by non-contrast computerized tomography scan can predict which patients will respond to β-blocker therapy with a reduction in exacerbation frequency.
Adding home noninvasive ventilation to home oxygen therapy was effective in patients with persistent hypercapnia following an acute exacerbation of COPD.
The national action plan released by the NHLBI aims to reduce the burden of COPD through collaboration with federal agencies, patients, advocates, and researchers.
The TRINITY study found that triple therapy significantly reduced the rate of COPD exacerbations.
The annual number of patients who died from COPD while in the hospital decreased 62% from 2005 to 2014.
Distinct differences occur between eosinophilic COPD and COPD patients with asthma.
Increased residual volume is associated with a larger pulmonary artery in patients with COPD.
The use of inhaled corticosteroids is associated with an increased risk of pneumonia in asthma patients.
Use of the empowerment approach is necessary for health promotion in older patients with COPD, but little attention has been paid to the dimensions of empowerment in COPD management.
Utibron Neohaler inhalation powder is indicated for the long-term maintenance treatment of airflow obstruction in patients with COPD.
The European Respiratory Society and the American Thoracic Society have released a guideline for the treatment of patients with COPD exacerbations.
A daily dose of atorvastatin could reduce pulmonary artery pressure among patients with COPD.
A novel technique involving NPPV reduced the risks of nosocomial infection, requirement for intubation, and hospital mortality in patients with COPD.
Researchers also observed no difference in 30-day mortality rates between patients in the ICU and those who received regular inpatient care in another hospital unit.
Countries committed to introducing policies such as high tobacco taxes and smoke-free public spaces.
A strong inverse association between total fruit and vegetable consumption and COPD was observed in smokers but not in never-smokers.
Patients receiving vitamin D for deficiency without bolus doses experienced the most benefit.
Polyvalent pneumococcal vaccines offered protection against community-acquired pneumonia in COPD patients.
Budesonide/formoterol treatment decreased exacerbations in COPD after 3 months.